As hereditary cancer risk assessment is increasingly incorporated into clinical care, clinicians may identify more patients who carry mutations in ovarian cancer risk genes beyond BRCA1 and BRCA2. The data presented here refines our understanding of the ovarian cancer risk and the typical age of diagnosis in women with PVs in moderate penetrance ovarian cancer-risk genes to inform safe and appropriate medical management. This evidence concerns the gene BRCA1 and hereditary cancer.